New Treatment for Drug Resistant Depression in Patients
Completed Phase 2 NCT03870776
Study Description
This study aims to find a new treatment for drug-resistant depression in patients who have not responded to traditional antidepressant therapies. The phase II, double-blind, randomized, placebo-controlled, multicenter trial includes 110 male or female patients aged 18 to 80 who have experienced at least two failed antidepressant treatments. The study will administer MAP4343 to those in the treatment group, with a placebo given in the control group. Patients will be recruited from psychiatric consultations at participating centers. This trial could lead to a new treatment option for those who suffer from drug-resistant depression.
Study Details
- Registry ID:
- NCT03870776
- Conditions:
- Depression
- Phase:
- Phase 2
- Target Enrollment:
- 126 participants
- Start Date:
- Age Range:
- 18–80 years
- Healthy Volunteers:
- No
Study Locations (11 sites)
-
CHU Henri Laborit
Poitiers, France -
CHD Vendée
La Roche-sur-Yon, France -
CHU Nantes
Nantes, France -
CHRU Tours
Tours, France -
CHU Angers
Angers, France -
CHU Besançon
Besançon, France -
Cabinet Médical Ambroise Paré
Élancourt, France -
APHP Hôpital La Pitié Salpétrière - Prinicipal investigator center
Paris, France -
Hôpital Ste Anne
Paris, France -
APHP La Pitié Salpétrière
Paris, France -
Hôpital Fontan 1
Lille, France
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.